Pharmamarketeer

Roche’s Rozlytrek receives US FDA approval to treat people with NTRK gene fusion─positive solid tumours

Roche announced that the US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1─positive, metastatic non─small cell lung cancer (NSCLC).

Medhc-fases-banner
Advertentie(s)